Literature DB >> 29850180

Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.

Jaseela Chiramel1, Rebecca Tay1, Raffaele Califano1,2,3.   

Abstract

Entities:  

Year:  2018        PMID： 29850180      PMCID： PMC5949435          DOI： 10.21037/jtd.2018.04.29

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.

Authors:  Kazuyuki Tsujino; Takayasu Kurata; Satomi Yamamoto; Tomoya Kawaguchi; Akihito Kubo; Shunichi Isa; Yoshikazu Hasegawa; Sai-Hong Ignatius Ou; Minoru Takada; Masahiko Ando
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

2.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

3.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

4.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.

Authors:  Andrew B Sharabi; Christopher J Nirschl; Christina M Kochel; Thomas R Nirschl; Brian J Francica; Esteban Velarde; Theodore L Deweese; Charles G Drake
Journal:  Cancer Immunol Res       Date:  2014-12-19       Impact factor: 11.151

5.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

9.  Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?

Authors:  Abigail T Berman; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2016-02

10.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245
View more
  2 in total

Review 1.  Why should radiation oncology do translational research? [corrected].

Authors:  Rut Cañas; Isabel Linares; Ferran Guedea; Miguel Ángel Berenguer
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-12

2.  Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.

Authors:  Qianqian Zhao; Yixing Chen; Shisuo Du; Xinrong Yang; Yanling Chen; Yuan Ji; Zhaochong Zeng
Journal:  Cancer Biol Ther       Date:  2021-03-15       Impact factor: 4.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.